The number and stimulatory phenotype of cDC1s in draining lymph nodes has been reported to decrease with tumor progression, and restoration of the cDC1s axis with Flt3L/anti-CD40 treatment resulted in the expansion of tumor-specific CD8+ T cells and a reduction in tumor burden [183]. The gene discussed is CD8A; the disease is neoplasm.